(±)-Salmeterol-d3 Xinafoate (3-hydroxymethyl-d2;α-d1)

(±)-Salmeterol-d3 Xinafoate (3-hydroxymethyl-d2; ?-d1) is a medication used in the management of asthma and chronic obstructive pulmonary disease (COPD). It belongs to a class of drugs known as long-acting beta-agonists (LABAs) and works by relaxing the muscles in the airways, making it easier to breathe. Chemically, (±)-Salmeterol-d3 Xinafoate is a combination of (±)-Salmeterol and Xinafoate. The d3 and d2 indicate that the medication has been deuterated, meaning that some of the hydrogen atoms in the molecule have been replaced with deuterium. This is a common technique used in the production of stable isotope-labeled compounds for use in research and drug development. (±)-Salmeterol-d3 Xinafoate is typically administered via inhalation using a metered-dose inhaler or a dry powder inhaler. The medication is absorbed into the bloodstream and has a half-life of about 5.5 hours. It is metabolized in the liver and excreted in the urine. While (±)-Salmeterol-d3 Xinafoate is generally considered safe and effective, it may cause side effects such as headache, tremors, and palpitations. It may also interact with other medications, so it is important to consult with a healthcare provider before use. Overall, (±)-Salmeterol-d3 Xinafoate is a valuable tool in the management of asthma and COPD, providing relief for those suffering from respiratory issues.